CN105105115A - Probiotics compound for crowds with blood types of A, B and O and method and application of probiotics compound - Google Patents
Probiotics compound for crowds with blood types of A, B and O and method and application of probiotics compound Download PDFInfo
- Publication number
- CN105105115A CN105105115A CN201510516430.3A CN201510516430A CN105105115A CN 105105115 A CN105105115 A CN 105105115A CN 201510516430 A CN201510516430 A CN 201510516430A CN 105105115 A CN105105115 A CN 105105115A
- Authority
- CN
- China
- Prior art keywords
- blood
- crowd
- type
- probio
- type blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 242
- 210000004369 blood Anatomy 0.000 title claims abstract description 242
- 150000001875 compounds Chemical class 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 16
- 239000006041 probiotic Substances 0.000 title abstract description 11
- 235000018291 probiotics Nutrition 0.000 title abstract description 11
- 230000000694 effects Effects 0.000 claims abstract description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 22
- 241000186011 Bifidobacterium catenulatum Species 0.000 claims description 30
- 241000301580 Butyricicoccus pullicaecorum Species 0.000 claims description 22
- 238000013461 design Methods 0.000 claims description 22
- 241001191217 Slackia isoflavoniconvertens Species 0.000 claims description 21
- 244000005700 microbiome Species 0.000 claims description 21
- 241001394655 Roseburia inulinivorans Species 0.000 claims description 15
- 230000000926 neurological effect Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000000968 intestinal effect Effects 0.000 abstract description 29
- 241000894006 Bacteria Species 0.000 abstract description 24
- 241000282414 Homo sapiens Species 0.000 abstract description 21
- 238000004458 analytical method Methods 0.000 abstract description 12
- 230000036039 immunity Effects 0.000 abstract description 11
- 230000036541 health Effects 0.000 abstract description 9
- 108090000623 proteins and genes Proteins 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 5
- 238000012163 sequencing technique Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 235000006694 eating habits Nutrition 0.000 abstract description 3
- 230000000813 microbial effect Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000001079 digestive effect Effects 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 35
- 238000011160 research Methods 0.000 description 26
- 239000013589 supplement Substances 0.000 description 25
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 23
- 210000001035 gastrointestinal tract Anatomy 0.000 description 23
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 22
- 208000002672 hepatitis B Diseases 0.000 description 22
- 210000000936 intestine Anatomy 0.000 description 22
- 230000001580 bacterial effect Effects 0.000 description 17
- 230000002265 prevention Effects 0.000 description 16
- 241000186000 Bifidobacterium Species 0.000 description 15
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 12
- 208000019425 cirrhosis of liver Diseases 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- 206010016654 Fibrosis Diseases 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 9
- 230000007882 cirrhosis Effects 0.000 description 9
- 206010060862 Prostate cancer Diseases 0.000 description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 8
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 description 8
- 235000019126 equol Nutrition 0.000 description 8
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 206010009900 Colitis ulcerative Diseases 0.000 description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 241001557932 Butyricicoccus Species 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- 208000008469 Peptic Ulcer Diseases 0.000 description 4
- 241000589516 Pseudomonas Species 0.000 description 4
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 210000005027 intestinal barrier Anatomy 0.000 description 4
- 230000007358 intestinal barrier function Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 208000011906 peptic ulcer disease Diseases 0.000 description 4
- 230000001502 supplementing effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000168254 Siro Species 0.000 description 3
- 241001657520 Slackia Species 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 230000007413 intestinal health Effects 0.000 description 3
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 3
- 150000002515 isoflavone derivatives Chemical class 0.000 description 3
- 235000008696 isoflavones Nutrition 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 238000009987 spinning Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- 241000605059 Bacteroidetes Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000394636 Lactobacillus mucosae Species 0.000 description 2
- 206010027304 Menopausal symptoms Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 241000566145 Otus Species 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000186046 Actinomyces Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010056328 Hepatic ischaemia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000605947 Roseburia Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000033692 susceptibility to 1 coronary heart disease Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- -1 thalline compound Chemical class 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a probiotics compound for crowds with the blood types of A, B and O and a method and application of the probiotics compound. A high throughput Roche 454 platform is used, the influences of individual differences of dietary habits, medical history, ages and the like of hosts are excluded, sequencing analysis is carried out on the intestinal flora 16S rRNA gene of the adult crowds, the differences of intestinal microbial diversity of the blood types of A, B and O are analyzed, difference intestinal florae influencing the individual health among the blood types of A, B and O are found, the probiotics compound for the blood types A, B and O is designed in an individualized mode on the basis that the roles played by difference probiotics on the human bodies are known and the susceptibility of the blood types A, B and O on different diseases is combined, and thus the functions and effects of preventing or treating diseases, improving the immunity of the human bodies, improving host intestinal flora composition, promoting digestive absorption of nutrient substances, restricting harmful bacteria and harmful substances and the like are achieved.
Description
Technical field
The invention belongs to biotechnology technical field, particularly a kind of based on the design of gut flora distributional difference for the probio compound of abo blood group crowd and method thereof and application.
Background technology
Probio refers to a class intestinal physiology bacterium of the life and health be beneficial to man, after taking in enough quantity, one or more special health benefits are produced to human body, comprise and improve gastrointestinal health, immunity moderation system, alleviate lactose intolerance, reduce cholesterol, Constipation and diarrhoea etc.Along with the health-care effect of probio is more and more understood by consumer and accepts, on market, probiotics preparation form is also more and more diversified, although be turned on the form sale of personalized production, personalized service, custom-component packaging, but major part is all based on conventional probios such as supplementary Bifidobacterium, lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosus and Lactobacillus plantarums, and is for general population.But along with we are to the understanding of human body intestinal canal flora, existing large quantity research reference class enteric microorganism composition is subject to the impact of host genetic and the extraneous factor such as environment, diet, the enteric microorganism property of there are differences between different crowd.Therefore, the gut flora difference of root consumer groups and the neurological susceptibility to disease thereof, the personalized probiotic supplemented goods that must design seem particularly important.Such as, market has been developed the antiallergy probiotic products for allergic constitution crowd design, it devises five kinds of thalline compound probiotics with customizing, and effectively improves allergic constitution, improves immunity.
In recent years, increasing scholar thinks to there is inevitable contacting between abo blood group and disease.From nineteen fifty-three, the Late Cambrian cancer of the stomach such as Aird are relevant with A blood group, cause many scholars to the exploration of disease and abo blood group relation thus.Have scholar to think, the polymorphism of mankind ABO and other blood group is the evolution selection result under environment and pathogen-mediated, there is some inevitable contacting between abo blood group and disease.After the 1st report blood group antigens A is relevant to incidence gastric cancer, A blood group and disease associating statistically has report always, but the result obtained is not quite similar, be such as domesticly reported in the crowd suffering from hypertension, diabetes and cancer of the stomach and hepatitis B in recent years, artificially many with A blood group; And the research of B blood group focuses mostly in the neurological susceptibility to pathogenic pathogen; The incidence of disease of O blood group crowd Esophageal carcinoma is minimum, but more easily obtains peptic ulcer.Therefore, the neurological susceptibility of disease is proved relevant with abo blood group.
In addition, research also confirms except the extraneous factor such as environment, diet, and this stable host genetic of abo blood group also affects the gut flora of the mankind.Harri
although confirm Deng people, in Finland white people, abo blood group is relevant with the difference that host intestine microorganism forms.But this research need more sample to ensure the repeatability of result and the interference reducing the field such as habits and customs, nutrition intake between individuality to ensure the validity of result.The more important thing is, the analysis of gut flora needs high-throughput techniques, to assess the concrete kind of difference bacterium.
Summary of the invention
In order to overcome the shortcoming of prior art with not enough, primary and foremost purpose of the present invention is to provide a kind of based on the method for gut flora distributional difference design for the probio compound of abo blood group crowd.The present invention utilizes high-throughout Roche 454 platform, get rid of host's eating habit, medical history, the impact of the individual differences such as age, for the gut flora 16SrRNA gene of large crowd through row sequencing analysis, analyze the difference of abo blood group intestine microbial diversity, find the otherness gut flora affecting individual health between abo blood group, and in the effect that understanding difference probio plays at human body, in conjunction with abo blood group on the basis of the neurological susceptibility of various disease, design the probio compound for abo blood group personalizedly, to realize prevention or disease therapy, improve body immunity, improve host intestine flora to form, promote digesting and assimilating of nutriment, suppress the effects such as the function such as harmful bacteria and harmful substance.
Another object of the present invention is to provide by said method obtain based on the method for gut flora distributional difference design for the probio compound of abo blood group crowd.
Another object of the present invention is to provide described based on the application of gut flora distributional difference design for the probio compound of abo blood group crowd.
Object of the present invention is achieved through the following technical solutions:
Based on the design of gut flora distributional difference for a method for the probio compound of abo blood group crowd, comprise the steps:
According to the result to abo blood group enteric microorganism difference; analyze difference probio in abo blood group effect and in conjunction with the neurological susceptibility of abo blood group to various disease; design the probio compound for abo blood group, to realize prevent disease, improve body immunity, to protect the effects such as healthy personalizedly.
1, for the probio compound of A type blood crowd, one or more of Bifidobacteriumcatenulatum and Slackiaisoflavoniconvertens are comprised.
The described probio compound for A type blood crowd in preparation for the application in the food of A type blood crowd or medicine.
2, for the probio compound of AB type blood crowd, comprise Slackiaisoflavoniconvertens, Butyricicoccuspullicaecorum and Roseburiainulinivorans one or more.
The described probio compound for AB type blood crowd in preparation for the application in the food of AB type blood crowd or medicine.
3, for the probio compound of Type B blood crowd, Butyricicoccuspullicaecorum is comprised.
The described probio compound for Type B blood crowd in preparation for the application in the food of Type B blood crowd or medicine.
4, for the probio compound of O type blood crowd, Lactobacillumucosa is comprised.
The described probio compound for O type blood crowd in preparation for the application in the food of O type blood crowd or medicine.
The present invention, relative to prior art, has following advantage and effect:
(1) one embodiment of the invention, to one or more probio compounds that A type blood crowd supplements Bifidobacteriumcatenulatum or Slackiaisoflavoniconvertens, can play some beneficial effect following.
A type blood crowd supplements one or more probio compounds being rich in Bifidobacteriumcatenulatum and the crowd of A type blood effectively can be prevented to suffer from chronic hepatitis B or prevent it to develop into hepatitis B related cirrhosis, or plays the effect of relief of symptoms or treatment to the A type blood crowd suffering from chronic hepatitis B and hepatitis B related cirrhosis.This is very low according to the people Bifidobacteriumcatenulatum content of A type blood in case study on implementation 3, and simultaneously the content of Bifidobacteriumcatenulatum is low has close contacting with the generation of chronic hepatitis B and hepatitis B related cirrhosis disease and development again.Therefore, supplement Bifidobacteriumcatenulatum to A type blood crowd, Bifidobacteriumcatenulatum realizes prevention and therapy relevant disease by recovering intestinal microflora, prevention bacterial migration, minimizing local intestinal cell factor and endotoxin release.
A type blood crowd supplements one or more probio compounds being rich in Bifidobacteriumcatenulatum prevention and therapy A type blood crowd can suffer from IBS.This is according in case study on implementation 3, the diversity of people's Bifidobacterium of A type blood is low, Bifidobacteriumcatenulatum content is very low, and the situation of this and IBS patient is perfectly in harmony.The people such as AngelePMKerckhoffs point out that the level of its Bifidobacterium of IBS patient and Bifidobacteriumcatenulatum all significantly reduce.This result illustrates that A type blood crowd needs supplementary Bifidobacteriumcatenulatum, suffers from A type blood crowd the effect that IBS plays prevention and therapy.
Supplement one or more probio compounds being rich in Slackiaisoflavoniconvertens for A type blood crowd, the effect of prevention breast cancer and prostate cancer and cranial vascular disease can be played the crowd of A type blood.This is because according to embodiment 3; Slackiaisoflavoniconvertens is not contained in A type blood Intestinal microorganism in abo blood group; and existing research confirms that isoflavones metabolism be a kind of can be the probio of equol by Slackiaisoflavoniconvertens; equol has prevention breast cancer and prostate cancer; angiocardiopathy preventing, osteoporosis; improve menopausal syndrome, neuroprotective, there is important effect anti-ageing aspect.Therefore, supplement one or more probio compounds being rich in Slackiaisoflavoniconvertens and effectively can reduce A type blood to the neurological susceptibility of preventing breast cancer and prostate cancer and cranial vascular disease.
For A type blood crowd personalized supplement one or more probio compounds being rich in Lactobacillumucosa, can prevent or treat A, type blood crowd suffers from intestines problem caused by intestinal barrier dysfunction.This is because according to embodiment 3, in abo blood group, in A type blood Intestinal microorganism, Lactobacillumucosa content is low, and Lactobacillumucosa is one can increase enteric epithelium layer barrier, the intestines problems such as IBS, IBD is especially comprised to intestines problem and plays treatment good action.
(2) one embodiment of the invention relate to AB type blood crowd, design one or more probio compounds of supplementary Slackiaisoflavoniconvertens, Butyricicoccuspullicaecorum, Roseburiainulinivorans personalizedly, some beneficial effect following can be played.
Supplement one or more probio compounds being rich in Slackiaisoflavoniconvertens for AB type blood crowd, can play the crowd of AB type blood and reduce the pathogenetic risk of coronary disease.This is because existing research confirms that the crowd of AB type blood has neurological susceptibility to coronary heart disease, simultaneously according to embodiment 3, not containing Slackiaisoflavoniconvertens in AB type blood Intestinal microorganism, and Slackiaisoflavoniconvertens is a kind of can be the probio of equol by isoflavones metabolism, equol has again prevention breast cancer and prostate cancer, the magical effect such as angiocardiopathy preventing.Therefore, need to supplement to the crowd of AB type blood one or more probio compounds being rich in Slackiaisoflavoniconvertens, suffer from the risk of coronary heart disease with the crowd reducing AB type blood.
For AB type blood crowd personalized supplement one or more probio compounds being rich in Butyricicoccuspullicaecorum, the crowd that can reduce AB type blood suffers from the risk of IBD.This is according to inventive embodiment 3, finds that the content of its Butyricicoccuspullicaecorum bacterial classification of AB type blood crowd is low, and it is found that non-O type blood has research and confirms to have the excessive risk suffering from CD.Therefore, promotion intestinal tissue that the butyric acid that the present invention utilizes Butyricicoccuspullicaecorum to produce can play is grown, is improved the effects such as body's immunity, regulating intestinal canal microorganism and electrolyte balance, by supplement one or more probio compounds being rich in Butyricicoccuspullicaecorum realize prevention and therapy AB type crowd suffer from IBD effect.
One embodiment of the invention relate to AB type blood crowd, design one or more probio compounds of supplementary Roseburiainulinivorans personalizedly, are formed to improve AB type blood crowd host intestine flora, promote intestinal health.This finds according to enforcement 3, and the Roseburiainulinivorans content of AB type blood is minimum, and Type B blood, all there is significant difference between O type blood crowd.And the butyric acid that Roseburiainulinivorans produces has with antibiotic outside the similar function such as antibacterial and antitumor, also have and regulate body metabolism, promote that intestinal tissue is grown, improved the effects such as body's immunity, regulating intestinal canal microorganism and electrolyte balance.Therefore, for AB type blood crowd personalized supplement one or more probio compounds being rich in Roseburiainulinivorans, the effect promoting AB type blood Intestinal health can be realized.
(3) for Type B blood crowd, supplement one or more probio compounds being rich in Butyricicoccuspullicaecorum personalizedly, the effect that prevention and therapy Type B blood crowd suffers from IBD can be played.
This is according to inventive embodiment 3, finds that the content of Type B blood crowd Butyricicoccuspullicaecorum bacterial classification is low, and it is found that non-O type blood has research and confirms to have the excessive risk suffering from CD.Therefore, the promotion intestinal tissue that the butyric acid that the present invention utilizes Butyricicoccuspullicaecorum to produce plays is grown, is improved the effects such as body's immunity, regulating intestinal canal microorganism and electrolyte balance, suffers from the effect of IBD risk or treatment IBD by supplementing one or more probio compounds realization reduction Type B crowd of being rich in Butyricicoccuspullicaecorum.
(4) for O type blood crowd, supplement one or more probio compounds being rich in Lactobacillumucosa personalizedly, prevention can be played and control O type blood crowd and suffer from the intestines problems such as peptic ulcer.
This is because have by reducing Gut barrie r permeability to the effect alleviating intestinal barrier dysfunction as the Lactobacillumucosa of probio, the compact siro spinning technology between preventing because of enteric epithelium confluent monolayer cells is damaged and the various intestines problems that cause.And according to embodiment 3, this research confirms that O type blood crowd Lactobacillumucosa content is very low, there is significant difference with Type B blood, and the crowd of O type blood has neurological susceptibility to peptic ulcer.Therefore, supplement by personalization one or more probio compounds being rich in Lactobacillumucosa, can prevent or treat O type blood crowd and suffer from relevant intestines problem.
Accompanying drawing explanation
Fig. 1 is the Firmicutes of enteron aisle bacterium and the ratio difference of Bacteroidetes between abo blood group in embodiment 3.
Fig. 2 be in embodiment 3 between abo blood group gut flora probio belong on otherness.
Detailed description of the invention
Below in conjunction with embodiment and accompanying drawing, the present invention is described in further detail, but embodiments of the present invention are not limited thereto.
The bacterial strain used below in an example, it is as follows that it buys information:
Bifidobacteriumcatenulatum, purchased from German Culture Collection (DSMZ), DSMNO.:16992 (
https: //www.dsmz.de/catalogues/details/culture/DSM-16992.html);
Slackiaisoflavoniconvertens，DSMNO.：22006(
https://www.dsmz.de/catal ogues/details/culture/DSM-22006.html)；
Butyricicoccuspullicaecorum, purchased from German Culture Collection (DSMZ), DSMNO.:23266 (
https: //www.dsmz.de/catalogues/details/culture/DSM-23266.html? t x_dsmzresources_pi5%255BreturnPid%255D=304);
Roseburiainulinivorans, purchased from German Culture Collection (DSMZ), DSMNO.:16841 (
https: //www.dsmz.de/catalogues/details/culture/DSM-16841.html? tx_ds mzresources_pi5%255BreturnPid%255D=304);
Lactobacillumucosa, purchased from German Culture Collection (DSMZ), DSMNO.:13345 (
https: //www.dsmz.de/catalogues/details/culture/DSM-13345.html).
Embodiment 1: the collection of human feces sample and blood sample
For getting rid of the impact of the individual differences such as host's eating habit, medical history, age, we recruit 171 male volunteers altogether.All volunteers are 20 to 30 years old, live in Chinese Guangdong and economize.In addition, they have normal type (BMI=18.5 ~ 24.9 kilogram/square metre), participate in investigation people in the past within one month, do not take antibiotic.Every participant completes detailed medical treatment, life style and diet surveys questionnaire.
After human feces sample collection, be chilled in-80 DEG C and preserve to extract faeces DNA, extract DNA concentration and integrality by ultramicrospectrophotometer nanodrop2000 and agarose gel electrophoresis analysis.Meanwhile, medical personnel's venous collection volunteer blood 2mL to EDTA.2K heparin tube, and by positive reverse type and reverse type precise Identification abo blood group.
Be that sample extracts the requirement that bacterial genomes DNA carries out intestinal microecology research and extracts high-quality fecal bacteria genomic DNA with ight soil, it is single that 171 parts of human feces of collection extract band through agarose gel electrophoresis qualification, do not occur obvious degradation phenomenon.Meanwhile, the faeces DNA concentration mentioned and purity all meet the requirements, and can be used for next step sequencing analysis.In addition, the blood group of 171 volunteers is determined according to the standard operation of bracket for blood grouping, wherein A type blood 51 people, Type B blood 48 people, O type blood 59 people, AB type totally 13 people.
The process of embodiment 2:16SrRNA gene sequencing and data is filtered and OTU statistics:
Build library with detecting qualified sample: using after qualified genomic DNA dilutes as template, primer 907R (CCGTCAATTCMTTTGAGTTT) and the V3-V5 district of primer 517F (ACTCCTACGGGAGGCAGCAG) to 16SrRNA gene is used to increase, magnetic bead screening fragment; Finally, emPCR and order-checking is carried out with qualified library.The data obtained with lower machine carry out next step analysis of biological information again.
Check order the initial data obtained, and there is a certain proportion of interfering data, in order to make the result of information analysis more accurate, reliable, first splicing initial data, filtering, obtaining valid data.Then, carry out OTUs cluster and species taxonomy analysis based on valid data, and OTU and species annotation are combined, thus obtain the OTUs of each sample and the fundamental analysis result of classification pedigree.
Checked order to fecal bacteria 16SrRNA gene by Roche454 platform, it is 1,717,845 that result obtains original series number, and average length is 454bp; After filtering, the total number of sequence is 992,198.Original series after filtration treatment, obtain 16srDNA filter after sequence and by the OTU that its cluster is for species taxonomy under 97% similarity, raw 4,788 OUT of 171 sample common properties.
Embodiment 3: different blood group Intestinal flora variance analysis
We are by calculating the Alpha diversity of enteric microorganism in abo blood group, and the individual intestine microbial diversity that result observes A type blood significantly declines.Table 1 is presented at that A type blood sample shannon index is minimum, and simpson index is maximum, and this illustrates that minimum (Shannon index is 2.59436, P<0.05 to the enteron aisle bacterium constituent species diversity of A type blood people; Simpson index is 0.16220, P<0.05, t inspection), the enteron aisle bacterium diversity of Type B blood people is the highest, and (Shannon index is 2.78766, P<0.05; Simpson index is 0.1307, P<0.05, t inspection).Human body intestinal canal microorganism species is the ecosystem of a bulky complex, it accounts for whole body micro-ecological bacterial sum about 80%, the diversity of its gut flora is extremely important, has a large amount of disease to reduce relevant as colorectal cancer (CRC), chronic hepatitis B patient, IBS (IBS) etc. are all proved with gut flora diversity.Therefore, the people of A type blood may more easily suffer from this type of disease.
Meanwhile, for determining the composition change of abo blood group enteric microorganism, we have studied the composition difference of abo blood group enteric microorganism in door level by statistical analysis.Interesting discovery, the enteric microorganism Firmicutes of the people of A type blood than the ratio of Bacteroidetes compared with other blood groups large (Fig. 1).The ratio the highest (F/B ratio is 6.29) of the microorganism F/B of the enteron aisle existence of the individuality of A type blood, and the individuality of AB type blood presents minimum F/B ratio (F/B ratio is 1.49).People's researchs such as Zhao, L show that the enteric microorganism of obese people and obesity mice has more greatly, more significant F/B ratio, and this may illustrate crowd more easily fat (Naturereviews, Microbiology, 2013 of A type blood; 11:639-647).
Belonging to in the detection of planting, we have also discovered the otherness of beneficial bacteria of intestinal tract composition and richness between abo blood group, and as shown in Figure 2, the difference of abo blood group in beneficial bacteria of intestinal tract kind is as shown in table 2 for the difference of abo blood group on beneficial bacteria of intestinal tract belongs to.
In abo blood group; as content in B and O type blood group of the Bifidobacterium (Bifidobacterium) of health barometer comparatively A and AB type enrich; wherein in A type blood the content of bifidobacterium catenulatum (Bifidobacteriumcatenulatum) bacterial classification comparatively Type B, O type blood significantly reduce (P=0.019; P=0.046); Bifidobacteriumcatenulatum, as the bacterial classification of in human body Bifidobacterium, has positive effect to protection human body intestinal canal health.
Slackia belongs to actinomyces door, is the important probio producing equol.Be rich in Slackia without (Type B blood and O type blood) in the blood group of Staphylococal Protein A, in A and AB type blood, content is then very low.Wherein, Slackiaisoflavoniconvertens bacterial classification is not even detected in A type and AB type.
Butyricicoccus is then that butyric acid produces bacterial strain, in the blood group (A type blood, O type blood) without B antigen with there is significant difference having between the blood group of B antigen (AB type blood, Type B blood), content wherein in O type blood is Type B blood high 32.4 times (P<0.05) even comparatively, than the individual height 8 times (P<0.05) of AB type blood.Wherein, Butyricicoccuspullicaecorum as a kind of can the probio of prevention and therapy IBD, the blood group (A type blood, O type blood) without B antigen and between the blood group (AB type blood, Type B blood) having B antigen assuming a marked difference property too.
Roseburia is a kind of probio that can produce butyric acid in human body, and its Roseburiainulinivorans has performance to be improved host intestine flora formation, improve the effects such as body's immunity.Roseburiainulinivorans abundance in AB type blood is low, all there is significant difference (P<0.05) compared with the blood group (Type B blood and O type blood) without Staphylococal Protein A.
Lactobacillus plays a part very important in human body intestinal canal, and more than the content of common old man lactic acid bacteria 60 times of long lived elder, has been widely used in many industries such as light industry, food, medicine and feed industry.Lactobacillus content in the crowd of Type B blood is the abundantest, wherein Lactobacillusmucosae comparatively A, O type all significant differences (P value is all less than 0.01) in Type B blood crowd.
Above-mentioned probio is studied according to us and confirms the content property of there are differences between different blood group, and simultaneously these difference probios provide strong foundation to the probio compound that we devise for the crowd of abo blood group with customizing that act as that health plays.Term " probio " herein refer to have healthy support effect any bacterial species, bacterial strain or its combination, be not limited to effect in current received bacterial strain or intestines.
Alpha Diversity analysis result between table 1 group
| Alpha diversity | mean(A) | SD(A) | mean(B) | SD(B) | mean(O) | SD(O) | mean(AB) | SD(AB) | p-vaule |
| sobs | 120.1429 | 52.91621 | 124.2449 | 53.15995 | 114.4 | 39.18976 | 127.8462 | 39.25737 | 0.60277 |
| chao | 236.6499 | 149.1622 | 238.4758 | 137.1572 | 222.6335 | 101.4782 | 203.8441 | 96.74061 | 0.87019 |
| ace | 330.6038 | 254.5619 | 367.0758 | 286.745 | 310.8907 | 191.5391 | 252.1566 | 124.8528 | 0.43783 |
| shannon | 2.59436 | 0.48882 | 2.78766 | 0.45264 | 2.66973 | 0.46521 | 2.76137 | 0.47386 | 0.0496 |
| simpson | 0.1622 | 0.08174 | 0.1307 | 0.08946 | 0.1468 | 0.07955 | 0.16018 | 0.0865 | 0.04745 |
The otherness of beneficial bacteria of intestinal tract in kind between table 2ABO blood group
Wherein, A represents A type blood, and B represents Type B blood, and C represents O type blood, and D represents AB type blood.
Embodiment 4
The present invention is based upon on the basis of embodiment 3: abo blood group beneficial bacteria of intestinal tract diversity there are differences, simultaneously in conjunction with the effect of this probio and abo blood group to the difference of disease susceptibility, for ABO type blood crowd personalized design containing one or more probio compounds.
1, the present invention is directed to A type blood, design one or more probio compounds supplementing and be rich in Bifidobacteriumcatenulatum personalizedly.
Bifidobacterium forms the major microorganisms of baby intestinal, also very abundant in adult, studies have found that the more common old man of the quantity of Bifidobacterium Bifidum in the enteron aisle of long lived elder obviously increases.Through large quantity research, numerous experts and scholars have confirmed that Bifidobacterium is flora the most useful in intestines, are the barometers of health, supplement Bifidobacterium and can prevent, treat enteric infection and diarrhoea etc.But current most method supplements Bifidobacterium on the whole, the level namely belonged to.And Bifidobacterium is by multiple different kind, it is in metabolism, enzymatic activity, and different with aspects such as the immune system effects of host, and not all Bifidobacterium is all applicable to A type blood crowd.And according to embodiment 3, we find that Bifidobacteriumcatenulatum content in A type blood is minimum, all there is significant difference with Type B blood and O type blood.Therefore, the present invention according to the discovery of embodiment 3, the effect of bifidobacterium catenulatum and A type blood to the neurological susceptibility of disease, personalized ground supplements for A type blood one or more probio compounds being rich in Bifidobacteriumcatenulatum, to prevention or alleviate, treat following relevant disease and play positive role.
The minimizing that research has confirmed Bifidobacteriumcatenulatum and chronic hepatitis B, hepatitis B related cirrhosis are closely bound up, and bifidobacterium catenulatum plays protection to liver and effectively acts on.The people such as MinXu find that in the patients with chronic liver of being induced by hepatitis B, Bifidobacterium sum significantly reduces, and research subsequently confirms that in the liver cirrhosis patient (HBVcirrhotics) that chronic hepatitis B patient (CHBpatients), hepatitis B are relevant, Bifidobacteriumcatenulatum all shows significant decline (MinXu etc., MicrobEcol, 2012; 63:304-313).The people such as XingHC find, Bifidobacteriumcatenulatum may be by recovering intestinal microflora, stop bacterial migration, reduce local intestinal cell factor and endotoxin release protects acute liver damage and the hepatic ischemia-reperfusion injury (people such as XingHC, JGastroenterolHepatol, 2006; 21:647-656).In addition, correlation research at present about abo blood group and chronic hepatitis B, cirrhosis and liver cancer all has report both at home and abroad, easily develops into cirrhosis after having research to point out A type blood trouble hepatitis, and canceration rate is far above other blood groups (people such as QiangLi, plosone, 2012; 7 (1): e29928).713 routine chronic hepatitis Bs and 879 healthy populations are compared by the people such as Ji Rong, point out that A type blood crowd suffers from the ratio of chronic hepatitis B and other blood groups exist significant difference, think that A type blood exists neurological susceptibility to chronic hepatitis B, this result (He Liping consistent with the result of study of He Liping, ChineseCommunityDoctors, 2012; 14 (28) .).
Therefore, one embodiment of the invention relate to supplements in one or more probio compounds to A type blood crowd, chronic hepatitis B, hepatitis B related cirrhosis can be suffered to the crowd of prevention A type blood by supplementing Bifidobacteriumcatenulatum to A type blood crowd, or alleviate, treat the A type blood crowd of trouble chronic hepatitis B, hepatitis B related cirrhosis.It can also use together with other the at present known medicine for chronic hepatitis B, hepatitis B related cirrhosis.
Bifidobacteriumcatenulatum is relevant with IBS (IBS) to have research to point out.IBS is that one changes relevant with gastrointestinal function, abnormal for cardinal symptom and the syndrome lacking intestines and stomach structure or biochemical exception with chronic or RAP, diarrhoea, bowl evacuation habit and stool.Research display, the level of IBS patient's Bifidobacterium is lower than health volunteer, and simultaneously in kind of level, in the ight soil of IBS patient and duodenum, Bifidobacteriumcatenulatum all significantly reduces (AngelePMKerckhoffs etc., WorldJGastroenterol, 2009; 15 (23): 2887-2892).This result to us A type blood crowd Bifidobacterium analyzed and the analysis result of Bifidobacteriumcatenulatum similar, the Bifidobacteriumcatenulatum content also showing A type blood in our embodiment 3 is minimum.
Therefore, one embodiment of the invention relate to one or more probio compounds supplementing Bifidobacteriumcatenulatum for A type blood crowd, prevention and therapy A type blood crowd can suffer from IBS.
2, for A, AB type blood, design one or more probio compounds of supplementary Slackiaisoflavoniconvertens personalizedly.
Slackiaisoflavoniconvertens is a kind of beneficial bacteria of intestinal tract be present in part human colon, and the isoflavones metabolism be extensively present in 300 various plants such as beans, cereal, fruit, vegetables can be equol by it.And equol has very high physiologically active, stable in properties, and by intestinal absorption.A large amount of epidemiology and clinical data show, equol is in prevention breast cancer and prostate cancer, and angiocardiopathy preventing, osteoporosis, improve menopausal syndrome, neuroprotective, and there is important effect anti-ageing aspect.But, according to embodiment 3, in abo blood group, A type blood and AB type blood crowd be not containing Slackiaisoflavoniconvertens, and being rich in Slackia Pseudomonas in Type B blood crowd and O type blood Intestinal, the content of Slackiaisoflavoniconvertens bacterial classification is all far away higher than A type blood and AB type blood simultaneously.
And having correlative study to show, A type blood is relevant with breast cancer and prostate cancer.The research display of the people such as Bai-LinZhang, the risk that the people of A type blood suffers from breast cancer is higher, and contrary O blood group can reduce the risk (people such as Bai-LinZhang, AsianPacificJournalofCancerPrevention, 2014 that suffer from breast cancer; 15 (11): 4643-4650).And 555 patients that the researcher of Tokyo medical university suffered from prostate cancer between 2004 ~ 2010 have carried out the rear discovery of follow-up study investigation, the male sex of O type blood is very low in the possibility of surgery recurrence after operation; By contrast, the possibility that the male sex of A type blood is recurred after surgery is the highest, is 35%.In addition, crowd's cranial vascular disease incidence of A type is higher, and crowd's coronary heart disease incidence of AB type is higher.
Therefore, for A, AB type blood crowd personalized design one or more probio compounds of supplementary Slackiaisoflavoniconvertens, can reduce suffer from breast cancer and the risk of prostate cancer, the generation of angiocardiopathy preventing.
3, for B, AB type blood crowd, supplement one or more probio compounds being rich in Butyricicoccuspullicaecorum personalizedly.
IBD (Inflammatoryboweldisease, IBD) comprises ulcerative colitis (Ulcerativecolitis, UC) and Crohn disease (Crohn ' sdisease, CD).Crohn disease (Crohn ' sdisease, CD) also known as regional enteritis, segmental enteritis or crohn's disease, relate to each section of alimentary canal taking anus from oral cavity, but be more common in terminal ileum and close on colon; pathology becomes interim or great-jump-forward distribution, is holostrome intestines wall inflammation.Ulcerative colitis (Ulcerativecolitis, UC) also known as nonspecific ulcerative colitis; pathology mainly involves colorectal mucosa and submucosa, rectum and lower distal colon are modal affected area, but also can involve total colectomy and terminal ileum when pathology is serious.In the treatment of IBD, application immunodepressant has a great development as the Main Means of this disease of clinical treatment, but still also exist expensive, toxic and side effect strong, and is not to problems such as all patients are effective.Long-Time Service antibiotic then easily causes enteric bacteria resistance and causes flora imbalance, often makes the state of an illness of IBD more complicated.
Although, the cause of disease of IBD is illustrated not yet completely and therapeutic scheme in the past exists a lot of drawback, but research has had breakthrough discovery recently, the people such as VenessaEeckhaut have studied its remarkable reduction compared with healthy population Butyricicoccus Pseudomonas of patient confirming to suffer from IBD.Butyricicoccuspullicaecorum has been proved to be a kind of probio being present in human body intestinal canal, can produce butyric acid in human body.And butyric acid is considered to antibiotic potential substitute, have stronger bactericidal action, butyric acid also has promotion growth of animal, strengthens the functions such as animal body immunity, regulating intestinal canal microorganism simultaneously.Therefore, researcher allows the oral Butyricicoccuspullicaecorum of IBD sufferer by visually observing and histological criterion, the reduced levels of enteron aisle MPer and tumor necrosis factor α (TNF α) and interleukin (IL)-12 can find that the enteron aisle of oral Butyricicoccuspullicaecorum to IBD patient plays the significant protective effect (people such as VenessaEeckhaut, Inflammatoryboweldisease, 2012; 62 (12): 1745-1752).
The present invention also obtains similar result by embodiment 3 in Type B and AB type crowd.We according to embodiment 3 find Type B blood, its Butyricicoccus Pseudomonas of AB type blood crowd level very low, and in O type blood crowd, the content of Butyricicoccus Pseudomonas is the abundantest; Simultaneously also all there is significant difference with O type and A type in the content of Type B blood, its Butyricicoccuspullicaecorum bacterial classification of AB type blood crowd, content obviously comparatively O type blood and A type blood low.In addition, the research of the people such as DiegoForni confirms, abo blood group sense of organization antigen may be correlated with to the neurological susceptibility of CD and affect the order of severity of disease.In CD sufferer, non-O type blood and nonsecreting type are proved to be a kind of high risk factor.
Therefore, this research is according to the discovery of embodiment 3, low and the non-O type blood of the content of Type B blood, its Butyricicoccuspullicaecorum bacterial classification of AB type blood crowd is to the neurological susceptibility of IBD, devise design personalizedly and supplement one or more probio compounds being rich in Butyricicoccuspullicaecorum, Type B blood can be prevented, AB type blood crowd suffer from intestines suffer from IBD, also can be reduced the toxic and side effect of Long-Time Service antibiotic therapy by the form of therapy IBD of probiotic supplemented compound simultaneously.
4, for AB type blood crowd, supplement one or more probio compounds being rich in Roseburiainulinivorans personalizedly.
Roseburiainulinivorans is a kind of probio that can utilize polysaccharide and produce butyric acid in human colon, and butyric acid is the one of SCFA, large quantity research shows that butyric acid is as a kind of organic acid, except having with antibiotic except the similar function such as antibacterial and antitumor, also having and regulating body metabolism, promote that intestinal tissue is grown, improved the effects such as body's immunity, regulating intestinal canal microorganism and electrolyte balance.Diabetes B patient characteristic is the imbalance of moderate intestinal microflora and produces butyrate bacteria abundance to decline to have researcher to find, Roseburiainulinivorans relative abundance value is less than critical value and is just diagnosed as one of standard of diabetes conditions state.This research finds according to enforcement 3, and the content of AB type is minimum, has between Type B blood, O type blood crowd and all there is significant difference.
Therefore, according to enforcement 3, for AB type blood crowd, supplement one or more probio compounds being rich in Roseburiainulinivorans personalizedly, strengthen AB type blood gut flora Roseburiainulinivorans abundance, improve host intestine flora and form, promote intestinal health.
5, for A, O type blood crowd, supplement one or more probio compounds being rich in Lactobacillumucosa personalizedly.
Lactobacillus mucosae (Lactobacillumucosa) is the lactic acid bacteria being present in human body intestinal canal, and the large quantity research of bacterium shows, lactic acid bacteria can regulate body composition of gut flora, keep microecological balance, improve food digestion rate and biological value, reduce serum cholesterol, control endotoxin, suppress the generation of corrupt bacteria growing breeding and spoilage product in enteron aisle, manufacture nutriment, stimulate tissue development, thus the nutritional status to body, physiological function, cell infection, drug effect, toxic reaction, immune response, tumour occurs, the generation effects such as aging course and unexpected emergency reaction.As can be seen here, the physiological function of lactic acid bacteria and the vital movement of body closely bound up.Can say, if lactic acid bacteria stops growing, humans and animals is just difficult to healthy existence.And Lactobacillumucosa can play good effect by reducing Gut barrie r permeability to alleviating intestinal barrier dysfunction, the intestines problems such as IBS, IBD especially being comprised to intestines problem and plays therapeutic action.Because there is compact siro spinning technology between normal enteric epithelium confluent monolayer cells, the transfer of restrictive substance from enteric cavity to intestinal mucosa is carried out as barrier, and compact siro spinning technology can be destroyed by some enteropathogens or by paathogenic factors such as pro-inflammatory cytokines, thus affect epithelial cells bypass permeability, contribute to comprising the various intestines problems such as IBD and IBS (people such as CLAYBURGH, LabInvest, 84,282-91,2004)).And the present invention is according to embodiment 3, finds that A, O type blood crowd Lactobacillumucosa content is very low, there is significant difference with Type B blood.And large quantity research confirm that the crowd of O type blood has neurological susceptibility to peptic ulcer, the crowd of A type blood is more easy to get CD.
Therefore, the present invention is directed to A, O type blood crowd, supplement one or more probio compounds being rich in Lactobacillumucosa personalizedly and can prevent or treat the intestines problem of A, O type blood crowd trouble caused by intestinal barrier dysfunction.
Above-described embodiment is the present invention's preferably embodiment; but embodiments of the present invention are not restricted to the described embodiments; change, the modification done under other any does not deviate from Spirit Essence of the present invention and principle, substitute, combine, simplify; all should be the substitute mode of equivalence, be included within protection scope of the present invention.
Claims (9)
1. design the method for the probio compound of abo blood group crowd based on gut flora distributional difference, it is characterized in that comprising the steps:
According to the result to abo blood group enteric microorganism difference, analyze the effect of difference probio in abo blood group and in conjunction with the neurological susceptibility of abo blood group to various disease, design the probio compound for abo blood group.
2., by the probio compound for A type blood crowd obtained for the method for the probio compound of abo blood group crowd based on the design of gut flora distributional difference according to claim 1, it is characterized in that comprising one or more of Bifidobacteriumcatenulatum and Slackiaisoflavoniconvertens.
3. by the probio compound for AB type blood crowd obtained for the method for the probio compound of abo blood group crowd based on the design of gut flora distributional difference according to claim 1, it is characterized in that comprising Slackiaisoflavoniconvertens, Butyricicoccuspullicaecorum and Roseburiainulinivorans one or more.
4., by the probio compound for Type B blood crowd obtained for the method for the probio compound of abo blood group crowd based on the design of gut flora distributional difference according to claim 1, it is characterized in that comprising Butyricicoccuspullicaecorum.
5., by the probio compound for O type blood crowd obtained for the method for the probio compound of abo blood group crowd based on the design of gut flora distributional difference according to claim 1, it is characterized in that comprising Lactobacillumucosa.
6. the probio compound for A type blood crowd according to claim 2 in preparation for the application in the food of A type blood crowd or medicine.
7. the probio compound for AB type blood crowd according to claim 3 in preparation for the application in the food of AB type blood crowd or medicine.
8. the probio compound for Type B blood crowd according to claim 4 in preparation for the application in the food of Type B blood crowd or medicine.
9. the probio compound for O type blood crowd according to claim 5 in preparation for the application in the food of O type blood crowd or medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510516430.3A CN105105115A (en) | 2015-08-21 | 2015-08-21 | Probiotics compound for crowds with blood types of A, B and O and method and application of probiotics compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510516430.3A CN105105115A (en) | 2015-08-21 | 2015-08-21 | Probiotics compound for crowds with blood types of A, B and O and method and application of probiotics compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105105115A true CN105105115A (en) | 2015-12-02 |
Family
ID=54653443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510516430.3A Pending CN105105115A (en) | 2015-08-21 | 2015-08-21 | Probiotics compound for crowds with blood types of A, B and O and method and application of probiotics compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105105115A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108165619A (en) * | 2017-12-29 | 2018-06-15 | 武汉轻工大学 | The feeding prebiotic bacterial screening method of anti-chicken C.perfringens infection |
| CN109988725A (en) * | 2018-06-26 | 2019-07-09 | 银川尧玥生物科技有限公司 | The preparation technique and application of reducing weight and blood fat microbial bacterial agent and its derivative |
| CN111455016A (en) * | 2020-03-18 | 2020-07-28 | 广州市华永睿健生物科技有限公司 | Establishment of intestinal microecological map of longevity family and application of intestinal microecological map in aging health field |
| CN115786175A (en) * | 2022-09-30 | 2023-03-14 | 广东省农业科学院动物卫生研究所 | Lactobacillus mucosae and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0489822A1 (en) * | 1989-08-31 | 1992-06-17 | The Biomembrane Institute | Abo genotyping |
| JP2004101249A (en) * | 2002-09-05 | 2004-04-02 | Meiji Milk Prod Co Ltd | Screening process of probiotics lactobacteriaceae |
| CN1622997A (en) * | 2002-03-26 | 2005-06-01 | 北京大学临床肿瘤学院 | Method for inspecting the genetic susceptibility of Helicobacter Pylorus related gastric carcinoma and the use thereof |
| CN102770154A (en) * | 2009-12-28 | 2012-11-07 | 芬兰血液红十字会 | Probiotic bifidobacterial composition in accordance with secretor blood group status |
-
2015
- 2015-08-21 CN CN201510516430.3A patent/CN105105115A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0489822A1 (en) * | 1989-08-31 | 1992-06-17 | The Biomembrane Institute | Abo genotyping |
| CN1622997A (en) * | 2002-03-26 | 2005-06-01 | 北京大学临床肿瘤学院 | Method for inspecting the genetic susceptibility of Helicobacter Pylorus related gastric carcinoma and the use thereof |
| JP2004101249A (en) * | 2002-09-05 | 2004-04-02 | Meiji Milk Prod Co Ltd | Screening process of probiotics lactobacteriaceae |
| CN102770154A (en) * | 2009-12-28 | 2012-11-07 | 芬兰血液红十字会 | Probiotic bifidobacterial composition in accordance with secretor blood group status |
Non-Patent Citations (4)
| Title |
|---|
| MäKIVUOKKO ET AL: ""Association between the ABO blood group and the human intestinal microbiota composition"", 《BMC MICROBIOLOGY》 * |
| 汪卫东: "健康人群HBV感染与血型相关性分析", 《现代医药卫生》 * |
| 王令??等: "复发性口疮与ABO血型的相关性研究", 《临床口腔医学杂志》 * |
| 董志伟: "Lewis血型物质与胃肠道肿瘤抗原(综述)", 《国际肿瘤学杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108165619A (en) * | 2017-12-29 | 2018-06-15 | 武汉轻工大学 | The feeding prebiotic bacterial screening method of anti-chicken C.perfringens infection |
| CN109988725A (en) * | 2018-06-26 | 2019-07-09 | 银川尧玥生物科技有限公司 | The preparation technique and application of reducing weight and blood fat microbial bacterial agent and its derivative |
| CN111455016A (en) * | 2020-03-18 | 2020-07-28 | 广州市华永睿健生物科技有限公司 | Establishment of intestinal microecological map of longevity family and application of intestinal microecological map in aging health field |
| CN115786175A (en) * | 2022-09-30 | 2023-03-14 | 广东省农业科学院动物卫生研究所 | Lactobacillus mucosae and application thereof |
| CN115786175B (en) * | 2022-09-30 | 2023-12-08 | 广东省农业科学院动物卫生研究所 | Lactobacillus mucosae and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liang et al. | Edible fungal polysaccharides, the gut microbiota, and host health | |
| CN108004189B (en) | Composite probiotic lactic acid bacteria powder and preparation method and application thereof | |
| Yang et al. | Value added immunoregulatory polysaccharides of Hericium erinaceus and their effect on the gut microbiota | |
| Zhang et al. | Impacts of gut bacteria on human health and diseases | |
| Nakata et al. | Inhibitory effects of laminaran and alginate on production of putrefactive compounds from soy protein by intestinal microbiota in vitro and in rats | |
| Wan et al. | Modulation of gut microbiota by Ilex kudingcha improves dextran sulfate sodium-induced colitis | |
| Liu et al. | Recent findings in Akkermansia muciniphila-regulated metabolism and its role in intestinal diseases | |
| CN103491969A (en) | Synbiotic compositions for restoration and reconstitution of gut microbiota | |
| CN105434476A (en) | Application of bacteroides fragilis to prevention and/or treatment of inflammatory bowel diseases (IBDs) | |
| Fu et al. | Clostridium butyricum ZJU-F1 benefits the intestinal barrier function and immune response associated with its modulation of gut microbiota in weaned piglets | |
| CN105105115A (en) | Probiotics compound for crowds with blood types of A, B and O and method and application of probiotics compound | |
| Schneedorf | Kefir D’Aqua and its probiotic properties | |
| Mu et al. | Probiotic yeast BR14 ameliorates DSS-induced colitis by restoring the gut barrier and adjusting the intestinal microbiota | |
| Hatanaka et al. | Effect of Bacillus subtilis C-3102 on loose stools in healthy volunteers | |
| Khangwal et al. | Prospecting prebiotics, innovative evaluation methods, and their health applications: A review | |
| Li et al. | Effects of in vitro digestion and fermentation of Nostoc commune Vauch. polysaccharides on properties and gut microbiota | |
| CN111415705A (en) | Method and medium for making related intestinal flora detection report | |
| CN102770154B (en) | The probiotic bifidobacterium compositions conformed to secretor blood group state | |
| Selvamani et al. | Efficacy of probiotics-based interventions as therapy for inflammatory bowel disease: a recent update | |
| Yamin et al. | Effect of Ganoderma lucidum polysaccharides on the growth of Bifidobacterium spp. as assessed using real-time PCR. | |
| Mishra et al. | Current trends in non-dairy based synbiotics | |
| Yang et al. | Effects of fenugreek seed extracts on growth performance and intestinal health of broilers | |
| Hao et al. | The biological regulatory activities of Flammulina velutipes polysaccharide in mice intestinal microbiota, immune repertoire and heart transcriptome | |
| CN114072071A (en) | Compositions and methods for affecting human intestinal microorganisms | |
| Sun et al. | Effects of Bacillus subtilis natto JLCC513 on gut microbiota and intestinal barrier function in obese rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151202 |
|
| RJ01 | Rejection of invention patent application after publication |